Cost Utility of Tumour Necrosis Factor-α Inhibitors for Rheumatoid Arthritis: An Application of Bayesian Methods for Evidence Synthesis in a Markov Model

By Nguyen Christine M.   Bounthavong Mark   Mendes Margaret A.S.   Christopher Melissa L.D.   Tran Josephine N.   Kazerooni Rashid   Morreale Anthony P.  

PharmacoEconomics, Vol. 30, Iss. 7, 2012-07 ,pp. : 575-593

Adis International

Access to resources Recommend Favorite

A Lifetime Markov Model for the Economic Evaluation of Chronic Obstructive Pulmonary Disease

By Menn Petra   Leidl Reiner   Holle Rolf  

PharmacoEconomics, Vol. 30, Iss. 9, 2012-09 ,pp. : 825-840

Adis International

Access to resources Recommend Favorite

Safety evaluation of leflunomide in rheumatoid arthritis

By I Keen Helen  

Expert Opinion on Drug Safety, Vol. 12, Iss. 4, 2013-07 ,pp. : 581-588

Informa Healthcare

Access to resources Recommend Favorite

Economic Evaluation of Etoricoxib versus Non-Selective NSAIDs in the Treatment of Osteoarthritis and Rheumatoid Arthritis Patients in the UK

By Adis International Limited  

PharmacoEconomics, Vol. 23, Iss. 7, 2005-01 ,pp. : 743-743

Adis International

Access to resources Recommend Favorite

Economic Comparison of Leflunomide and Methotrexate in Patients with Rheumatoid Arthritis: An Evaluation Based on a 1-Year Randomised Controlled Trial

By Maetzel A.  

PharmacoEconomics, Vol. 20, Iss. 1, 2002-01 ,pp. : 61-70

Adis International

Access to resources Recommend Favorite